AbbVie’s blood cancer drug meets late-stage trial goals
AbbVie said its drug for a type of blood cancer met the main goals of a late-stage trial.
Story updates
01:28:50 PM UTC
SquawkNews
AbbVie NYSE:ABBV said on Thursday its therapy for a type of blood cancer has met the main goals of a late-stage trial.The therapy, etentamig, showed an overall response rate (ORR) of 74%, higher than the 45.7% recorded by standard treatments chosen by the trial investigator. ORR is the percentage o…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.